What is CAGR? What does CAGR table indicate for Bal Pharma Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Bal Pharma Ltd Stock Analysis

Q: Is Bal Pharma Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Bal Pharma Ltd and arrived at the following conclusion.

Q: Is the current market price of Bal Pharma Ltd a good price to buy it?

The 5-year analysis of Bal Pharma Ltd's performance infers.

Small Cap

Evaluated by 465 users | BSE: 524824 | NSE: BALPHARMA |
Pharmaceuticals & Drugs

Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous...

10 Year X-Ray

Standalone basis Standalone basis P Consolidated basis P

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Capital Employed	5.33%	8.9%	9.79%	9.73%	7.87%	5.75%	6.92%	7.64%	8.95%	-0.26%

Growth Parameters	Growth Parameters Colour Code Guide

Net Sales (Rs. Cr.)	114	140	148	179	187	198	226	208	223	171
Y-o-Y Gr. Rt.	-	22.1%	5.9%	20.9%	4.6%	5.6%	14.3%	-8.1%	7.4%	-23.5%
Adjusted EPS (Rs.)	0.16	3.17	3.75	4.26	2.8	1.65	2.34	3.54	4.59	-6.59
Y-o-Y Gr. Rt.	-	1881.3%	18.3%	13.6%	-34.3%	-41.1%	41.8%	51.3%	29.7%	-243.6%
Book Value per Share (Rs.)	34.64	37.88	41.06	43.48	41.63	42.48	46.98	50.97	54.23	46.53
Adjusted Net Profit	0.2	3.4	4	4.7	3.6	2.1	3.3	5	6.5	-9.3
Net Op. Cash Flow (Rs. Cr.)	11.3	12.9	16.1	13.3	14.4	1.3	6.4	12.6	11.6	21.6
Debt to Cash Flow from Ops	5.11	4.42	3.3	3.92	3.44	54.55	11.65	7.2	9.05	4.61

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Bal Pharma Ltd. ?

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

Bal Pharma Ltd. should be analysed on a Standalone basis

CAGR CAGR Colour Code Guide

	9 yrs	5 yrs	3 yrs	1 yr
Net Sales	4.5%	-1.8%	-8.9%	-23.5%
Adjusted EPS	-251.2%	-218.7%	-241.2%	-243.6%
Book Value per Share	3.3	2.3	-0.3	-14.2
Share Price	12.9%	-9.7%	-9%	30.5%

Key Financial Parameter	Performance Ratio Colour Code Guide

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Equity (%)	0.46	8.75	9.37	10	6.82	3.78	5.38	7.22	8.73	-13.07
Operating Profit Margin (%)	9.42	10.81	11.64	9.99	9.37	8.67	8.9	11.03	9.18	4.16
Net Profit Margin (%)	0.14	2.4	2.68	2.65	1.92	1.07	1.47	2.42	2.92	-5.47
Debt to Equity	1.59	1.43	1.23	1.08	0.92	1.28	1.11	1.25	1.36	1.51
Working Capital Days	231	211	215	189	193	211	221	290	303	386
Cash Conversion Cycle	113	103	95	76	72	71	78	112	129	179

Management X-Ray

Shareholding Pattern

Entity	Percentage Holding
Promoters	44.98%
Non-Institutions	55.02%

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

FAQs

1. Is Bal Pharma Ltd a good quality company?

Data is not available for this company.

2. Is current market price of Bal Pharma Ltd a good price to buy it?

The 5-year analysis of Bal Pharma Ltd's performance infers:

Bal Pharma Ltd earnings have declined by -218.7%, whereas share price has depreciated -9.7% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

3. What is Bal Pharma Ltd share price return in the past 10 years ?

We analysed the performance of Bal Pharma Ltd share prices over the last 10 years. Here is what we found out:

Bal Pharma Ltd share price has depreciated 8.3% annually over the past ten years.

About Company

The company exports APIs to countries like Japan, Australia,

The company exports APIs to countries like Japan, Australia, Spain, UK, Canada, Nigeria, Iceland, Slovenia, Romania, Argentina, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, Turkey, Egypt, Korea, Venezuela, Italy, Portugal, Morocco, Poland, Netherlands, Syria, Bangladesh, and Indonesia, etc.

It offers products for treatment for diabetes, cardiometabolics, gynaecology, dermatology, gastroenterology, orthopaedics, ENT and multi-speciality segments.

In India, the company operates its marketing through 5 divisions namely Multi-Specialty, Glyduz, Servetus, Bal Vedics and Zennova. It has distribution network of 1000 wholesalers that caters over 1,00,000 retailers.

The company produces range of APIs that includes Anti Histamine, Platelet inhibitor, Antidiabetic, Anti Convulsant, urinary incontinence, Neuropathic pain, Anti allergy, Anti inflammatory, Diuretic, Acne Treatment etc

Bal Pharma's R&D unit is engaged in developing processes for novel bulk actives (active pharmaceutical ingredients, APIs) and new chemical substances for therapeutic applications.

The companyâ€™s manufacturing facilities has been approved by WHO-GMP and has obtained the ISO 9001:2000 accreditations for quality management.

Businesses

API / Intermediates
Finished Formulations
Ayurvedic
Research and Development

Future Plans

Bal Pharma is planning to set up new facility in Uttaranchal, with an objective to enter into regulated markets. The company also plans to foray in the business of contract manufacturing.

Read Less